Stockscreener 앱 받기
1.79%
전일 마감가:
$447.28
열려 있는:
$444.4
하루 거래량:
1.68M
Relative Volume:
0.63
시가총액:
$237.48B
수익:
$37.30B
순이익/손실:
$7.80B
주가수익비율:
30.55
EPS:
14.3793
순현금흐름:
$8.60B
1주 성능:
+1.57%
1개월 성능:
+8.17%
6개월 성능:
+26.00%
1년 성능:
+49.97%
1일 변동 폭
$439.07
$444.59
1주일 범위
$424.74
$450.98
52주 변동 폭
$288.00
$450.98
암젠 Stock (AMGN) Company Profile
명칭
Amgen Inc
전화
(805)447-1000
주소
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
439.26 | 237.48B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,273.46 | 1.14T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
263.81 | 635.07B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
285.64 | 504.76B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.27 | 358.41B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
151.12 | 287.24B | 54.66B | 13.58B | 16.05B | 7.0171 |
암젠 Stock (AMGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-08 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2026-08-05 | 재확인 | BMO Capital Markets | Outperform |
| 2026-08-05 | 재확인 | BofA Securities | Underperform |
| 2026-08-05 | 재확인 | Canaccord Genuity | Hold |
| 2026-08-05 | 재확인 | Morgan Stanley | Equal-Weight |
| 2026-08-05 | 재확인 | Oppenheimer | Outperform |
| 2026-08-05 | 재확인 | RBC Capital Mkts | Outperform |
| 2026-08-05 | 재확인 | Robert W. Baird | Underperform |
| 2026-08-05 | 재확인 | Truist | Hold |
| 2026-08-05 | 재확인 | Wells Fargo | Equal Weight |
| 2026-05-05 | 다운그레이드 | Erste Group | Buy → Hold |
| 2026-04-21 | 개시 | Canaccord Genuity | Hold |
| 2026-03-10 | 개시 | Jefferies | Hold |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-01-20 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-12-05 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-11-24 | 재개 | Truist | Hold |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-03 | 재개 | Raymond James | Mkt Perform |
| 2025-05-20 | 재개 | Guggenheim | Neutral |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2024-09-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2024-05-03 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 재개 | Raymond James | Mkt Perform |
| 2024-02-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 업그레이드 | Truist | Hold → Buy |
| 2023-10-20 | 재개 | JP Morgan | Neutral |
| 2023-10-17 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 재개 | BofA Securities | Neutral |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-04-24 | 재확인 | Oppenheimer | Outperform |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 재확인 | Truist | Buy |
| 2022-11-18 | 개시 | Credit Suisse | Underperform |
| 2022-10-31 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2022-10-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-09 | 재확인 | Barclays | Equal Weight |
| 2022-02-09 | 재확인 | Jefferies | Buy |
| 2022-02-09 | 재확인 | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 재확인 | Oppenheimer | Outperform |
| 2022-02-09 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-09-23 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 개시 | Daiwa Securities | Buy |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | 업그레이드 | Truist | Hold → Buy |
| 2020-10-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | 다운그레이드 | Truist | Buy → Hold |
| 2020-10-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 재개 | Guggenheim | Neutral |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-03-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-17 | 재개 | Morgan Stanley | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-05-23 | 업그레이드 | Citigroup | Neutral → Buy |
모두보기
암젠 주식(AMGN)의 최신 뉴스
Why Healthcare ETFs Are Hovering Around One-Year Highs - Zacks Investment Research
Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? - The Motley Fool
Amgen stock hits all-time high at 447.09 USD By Investing.com - Investing.com Canada
Amgen Foundation Tops $75 Million in Hands-On Biotechnology Education, Reaching 100,000 Students a Year - CSRwire
The Escalator: CSL, Insmed, Amgen and more - Medical Marketing and Media
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? - The Motley Fool
Amgen Inc. $AMGN Shares Sold by Foster Victor Wealth Advisors LLC - MarketBeat
35,730 Amgen Inc. $AMGN Shares Acquired by Crossmark Global Holdings Inc. - MarketBeat
Amgen (AMGN) Sales Grew 10%, but Can Earnings Catch Up to the Price? - Yahoo Finance
Biotech ETF (BBH) Hits New 52-Week High - Zacks Investment Research
Amgen, AstraZeneca Detail Phase III Data For Tezspire’s Likely Third Indication - Scrip
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Amgen Inc (AMGN) Shares Surge 3.3% -- What GF Score of 85 Tells Investors - GuruFocus
2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going) - The Motley Fool
AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026 - PR Newswire
Amgen (AMGN) and AstraZeneca Report Positive Phase 3 Trial Resul - GuruFocus
From Discovery to Delivery: 5 Ways Amgen Is Putting Sustainability into Practice - www.marketscreener.com
AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study - Benzinga
Amgen, AstraZeneca report phase 3 results for Tezspire in eosinophilic esophagitis - Seeking Alpha
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial - Reuters
TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS - Amgen
Amgen Inc. $AMGN Stock Bought by Sumitomo Mitsui DS Asset Management Company Ltd - MarketBeat
Dona’s Story: Strengthening Her Bones After a Postmenopausal Osteoporosis Diagnosis - Amgen
10,773 Amgen Inc. $AMGN Shares Sold by Novem Group - MarketBeat
Greg Jennings LLC Buys New Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (AMGN) options chain - Yahoo Finance Australia
Mattel appoints Amgen's Peter Griffith as CFO, succeeding Paul Ruh - Reuters
Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight - GlobeNewswire Inc.
Amgen Has the Drugs and the Dividend. Now It Needs the Growth - Yahoo Finance
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Amgen Inc. $AMGN Stock Sold by First Bank & Trust - MarketBeat
2,560 Amgen Inc. $AMGN Shares Sold by Generali Investments Management Co LLC - MarketBeat
Beat the Market the Zacks Way: Valero Energy, Hagerty, Palantir in Focus - Zacks Investment Research
Amgen Inc. $AMGN Position Lifted by IFP Advisors Inc - MarketBeat
Amgen Inc. $AMGN Stock Sold by TD Waterhouse Canada Inc. - MarketBeat
Amgen Inc. $AMGN Stock: Frank Rimerman Advisors LLC Raises Holdings - MarketBeat
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider - Zacks Investment Research
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase? - Zacks Investment Research
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down - Zacks Investment Research
Here's Why Amgen (AMGN) is a Strong Momentum Stock - Zacks Investment Research
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? - The Motley Fool
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? - The Motley Fool
Amgen (AMGN) Laps the Stock Market: Here's Why - Zacks Investment Research
A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens - The Motley Fool
J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold? - Zacks Investment Research
Stock Market News for Oct 8, 2026 - Zacks Investment Research
Amgen (AMGN) Advances While Market Declines: Some Information for Investors - Zacks Investment Research
암젠 (AMGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
암젠 주식 (AMGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Khosla Rachna | SVP, Business Development |
Aug 13 '26 |
Sale |
416.43 |
1,252 |
521,365 |
6,404 |
| Khosla Rachna | Officer |
Aug 13 '26 |
Proposed Sale |
412.76 |
1,252 |
516,775 |
0 |
| Khosla Rachna | SVP, Business Development |
Aug 11 '26 |
Sale |
412.57 |
2,000 |
825,134 |
6,404 |
| Khosla Rachna | Officer |
Aug 11 '26 |
Proposed Sale |
414.21 |
2,000 |
828,420 |
0 |
| Derek Miller | Officer |
Aug 06 '26 |
Proposed Sale |
404.85 |
3,890 |
1,574,866 |
0 |
| Grygiel Nancy A. | Officer |
Aug 06 '26 |
Proposed Sale |
447.17 |
2,670 |
1,193,940 |
0 |
| Grygiel Nancy A. | SVP & CCO |
Aug 06 '26 |
Option Exercise |
177.41 |
2,970 |
526,906 |
9,310 |
| Miller Derek | SVP, Human Resources |
Aug 06 '26 |
Option Exercise |
169.56 |
3,890 |
659,574 |
14,531 |
| Miller Derek | SVP, Human Resources |
Aug 06 '26 |
Sale |
402.54 |
3,890 |
1,565,898 |
12,462 |
| Grygiel Nancy A. | SVP & CCO |
Aug 06 '26 |
Sale |
402.16 |
2,970 |
1,194,415 |
7,340 |
0.63%
자본화:
|
볼륨(24시간):